In 331 adults with overweight or obesity in Japan and Taiwan, cagrilintide-semaglutide reduced bodyweight by 18.4% vs 11.9% with semaglutide alone at 68 weeks (difference -6.5 points); gastrointestinal adverse events 53% vs 51%.
RCTn = 331
Yamauchi et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial